Eupraxia Pharmaceuticals (EPRXF) Stock Price, News & Analysis

Company Overview

Eupraxia Pharmaceuticals Inc. is a Canadian clinical-stage biotechnology company developing locally administered therapies designed to provide targeted treatment while limiting unwanted systemic exposure. The company uses its proprietary Diffusion technology to formulate medicines for controlled and sustained release at specific sites in the body.

Eupraxia’s lead product candidate is EP-104I, an investigational injectable formulation of dexamethasone acetate being developed for the treatment of pain and inflammation associated with knee osteoarthritis. The company’s pipeline has also included locally delivered therapies for other inflammatory and gastrointestinal conditions, although these programs remain subject to clinical and regulatory development.

Founded in 2011 and based in Victoria, British Columbia, Eupraxia conducts research and clinical-development activities through collaborations and trials in North America. The company does not currently market an approved commercial product, and its drug candidates remain dependent on the results of clinical studies and regulatory review.

Key Stats

• Today's Range: C$7.34 to C$7.75
• 50-Day Range: C$6.34 to C$9.10
• 52-Week Range: C$2.93 to C$6.78
• Volume: 637,045 shs
• Average Volume: 7,410 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: OTCMKTS:EPRXF
• CIK: N/A
• Web: www.eupraxiapharma.com
• Phone: 250 590 3968
• Fax: N/A
• Employees: 21
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A